Sequential Segmental Treatment of Emphysema With Upper Lobe Predominance (STEP-UP) Study

NACompletedINTERVENTIONAL
Enrollment

69

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

October 31, 2015

Study Completion Date

October 31, 2015

Conditions
Emphysema
Interventions
DEVICE

InterVapor® treatment plus Optimal Medical Therapy

Patients will be treated with the InterVapor System in 1 to 2 segments in the upper lobes of each lung (2 to 3 segments total). Patients will also receive Optimal Medical Therapy. Guidelines for prescribing medical treatment for emphysema are published by the American Thoracic Society (ATS) and the National Heart Lung and Blood Institute/World Health Organization (NHLBI/WHO GOLD workshop summary).

OTHER

Optimal Medical Therapy

Patients will receive Optimal Medical Therapy. Guidelines for prescribing medical treatment for emphysema are published by the American Thoracic Society (ATS) and the National Heart Lung and Blood Institute/World Health Organization (NHLBI/WHO GOLD workshop summary).

Trial Locations (17)

7

Mater Misericordiae University Hospital, Dublin

1051

Auckland City Hospital, Auckland

1140

Otto-Wagner-Spital, Vienna

3004

The Alfred Hospital, Melbourne

4032

Prince Charles Hospital, Chermside

5000

Royal Adelaide Hospital, Adelaide

6009

Sir Charles Gairdner Hospital, Nedlands

10117

Charite Universitätsmedizin Berlin Campus Mitte, Berlin

14089

Gemeinschaftskrankenhaus Havelhöhe Berlin, Berlin

21075

Asklepios Klinik Harburg, Hamburg

58675

Lungenklinik Hemer, Hemer

69126

Thoraxklinik Heidelberg, Heidelberg

82131

Asklepios Fachkliniken Gauting München, Gauting

90419

Klinikum Nürnberg, Nuremberg

Unknown

Klinik Schillerhohe, Gerlingen

Universitätsklinik Halle, Halle

Royal Bromptom & Harefield NHS Foundation, London

All Listed Sponsors
lead

Uptake Medical Corp

INDUSTRY

NCT01719263 - Sequential Segmental Treatment of Emphysema With Upper Lobe Predominance (STEP-UP) Study | Biotech Hunter | Biotech Hunter